Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Jennifer Smith

Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.

News

Treatments linked to death in COVID patients with thoracic cancers

Author:
Jennifer Smith
Publish date: June 29, 2020

Prior treatment with steroids, anticoagulants, chemotherapy alone, or chemo plus immunotherapy were all associated with an increased risk of death...

  • Read More

News

Nivolumab approved to treat esophageal squamous cell carcinoma

Author:
Jennifer Smith
Publish date: June 11, 2020

Nivolumab is approved for use in previously treated, unresectable, advanced, recurrent, or metastatic esophageal...

  • Read More

News

Frontline nivo-ipi plus chemo approved for metastatic NSCLC

Author:
Jennifer Smith
Publish date: May 27, 2020

The combination of nivolumab, ipilimumab, and platinum-doublet chemotherapy is approved as frontline treatment...

  • Read More

News

FDA approves brigatinib and companion diagnostic for NSCLC

Author:
Jennifer Smith
Publish date: May 27, 2020

The FDA approved brigatinib to treat adults with ALK-positive metastatic non–small cell lung cancer and approved...

  • Read More

News

FDA expands approval of atezolizumab in NSCLC

Author:
Jennifer Smith
Publish date: May 20, 2020

Atezolizumab is approved as first-line monotherapy for adults with metastatic non–s...

  • Read More

News

FDA approves olaparib/bevacizumab maintenance

Author:
Jennifer Smith
Publish date: May 11, 2020

The FDA has approved a new indication for olaparib and a companion diagnostic for adults with advanced...

  • Read More

News

NSCLC: FDA approves capmatinib and companion assay

Author:
Jennifer Smith
Publish date: May 6, 2020

Capmatinib is the first FDA-approved treatment for NSCLC with MET exon 14 skipping mutations.

  • Read More

News

Antitumor treatment may increase risk of severe events in COVID-19 patients

Author:
Jennifer Smith
Publish date: May 1, 2020

Receiving antitumor treatment within 14 days of COVID-19 diagnosis was linked to a higher risk of ICU admission...

  • Read More

News

Metastatic cancer linked to worse outcomes of COVID-19

Author:
Jennifer Smith
Publish date: April 29, 2020

Patients with hematologic malignancies or metastatic cancers had particularly high risks of developing severe or...

  • Read More

News

Mitomycin approved for low-grade upper tract urothelial cancer

Author:
Jennifer Smith
Publish date: April 15, 2020

The FDA’s fast-track approval of mitomycin is based on results from the phase 3 OLYMPUS trial.

  • Read More

News

Barriers to clinical trial participation revealed by gynecologic cancer patients

Author:
Jennifer Smith
Publish date: March 31, 2020

A survey suggests a lack of discussion about clinical trials between doctors and patients with gynecologic cancers.

  • Read More

News

Doublet may be beneficial in wild-type, advanced NSCLC

Author:
Jennifer Smith
Publish date: March 19, 2020

About 77% of patients achieved a partial response or had stable disease on combination apatinib and vinorelbine.

  • Read More

News

Drug reduces oral mucositis without affecting tumor control

Author:
Jennifer Smith
Publish date: March 10, 2020

Locoregional control, distant metastasis, and survival rates were similar in patients who received the drug, GC4419, and those who did not.

  • Read More

Article

Researchers honored by ACS, IASLC

Author:
Jennifer Smith
Publish date: March 9, 2020

The ACS has awarded the 2020 Medal of Honor to three researchers, and the IASLC has named a lectureship after a...

  • Read More

News

10-year data show no benefit when adding cetuximab to radiation and cisplatin

Author:
Jennifer Smith
Publish date: March 3, 2020

There was no survival benefit when cetuximab was added to radiotherapy and cisplatin in patients with head and neck carcinoma.

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close